Share This Page
Drug Price Trends for NDC 00078-0697
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0697
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0697
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-0697: A Comprehensive Review
Introduction
The pharmaceutical landscape is a complex, dynamic environment influenced by regulatory policies, patent statuses, market demand, manufacturing costs, and competitive pressures. This analysis examines NDC 00078-0697, a pharmaceutical product currently evaluated for its market positioning, pricing strategies, and future projections. Precise data indicates that NDC 00078-0697 is a therapeutic agent targeted toward specific medical indications, with a notable presence in both specialty and hospital settings.
Product Profile and Current Market Position
NDC 00078-0697 corresponds to Erythropoietin Alfa (Epogen, Procrit), a recombinant human erythropoietin used primarily to treat anemia associated with chronic kidney disease, chemotherapy, and certain surgical procedures. As a biosimilar or branded product, its market share is shaped by patent exclusivity, competition from biosimilars, and adoption within hospital formularies.
In 2022, Erythropoietin Alfa maintained a substantial market share, driven by clinical efficacy and established familiarity among healthcare providers. The product's revenues mirror the broader demand for anemia management, with an estimated global sales volume surpassing $3 billion annually[1].
Market Dynamics
Regulatory Status and Patent Landscape
While patent protections for original formulations like Epoetin Alfa have expired or are nearing expiration in several jurisdictions, biosimilar versions have entered the market, intensifying competition. The expiration of patents globally catalyzes price erosion and accelerates generics/biosimilars' market penetration.
In the U.S., the FDA has approved multiple biosimilar versions, notably Retacrit and Abecma, which exert downward pressure on branded prices. The competitive landscape is further shaped by regulatory pathways, reimbursement policies, and payer dynamics.
Therapeutic Alternatives and Competition
The primary competitors include biosimilar erythropoietins and alternative anemia treatments like darbepoetin alfa. The degree of interchangeability hinges on physician prescribing habits, insurance coverage, and perceived efficacy.
Market penetration of biosimilars in the U.S. is growing, with estimates indicating biosimilars capturing approximately 40-50% of the erythropoietin market by 2025[2]. This shift influences pricing strategies significantly.
Global Market Considerations
Emerging markets present growth opportunities driven by increasing healthcare access and generic adoption. However, pricing remains sensitive to local regulatory frameworks and economic conditions, resulting in wide price variability.
Pricing Analysis and Projections
Historical Price Trends
Before patent expiry, the average wholesale price (AWP) for Erythropoietin Alfa hovered around $140–$180 per 1,000-unit vial[3]. Post-patent expiry, biosimilar entries in the U.S. and Europe have led to price reductions of approximately 30-50%, depending on the market and payer negotiations.
In hospitals, negotiated acquisition costs often fall below AWP, with current effective prices for biosimilars averaging $80–$120 per 1,000 units[4].
Current Price Landscape
As of 2023, Erythropoietin Alfa (NDC 00078-0697) is priced at an estimated average of $85–$100 per unit in the U.S. hospital setting, reflecting competition from biosimilars and economies of scale. This is consistent with recent market data indicating a further decline compared to pre-expiry pricing.
In outpatient retail pharmacies, retail prices typically range between $150–$200 per dose, though insurance coverage often minimizes out-of-pocket costs due to reimbursement arrangements.
Future Price Projections (2023-2030)
Considering patent expirations, biosimilar market entry, and evolving reimbursement policies, prices are projected to decrease further:
- 2023-2025: Continued price erosion of approximately 10-15% annually. Biosimilar uptake accelerates, leading to prices stabilizing near $60–$80 per unit.
- 2026-2030: Market stabilization, with prices reaching $50–$70 per unit, driven by increased biosimilar adoption and potential introduction of next-generation erythropoietins with improved efficacy or dosing convenience.
- Price reductions may be moderated by factors such as supply chain disruptions, manufacturing challenges, and regulatory delays in biosimilar approval in certain regions.
Market Opportunities and Risks
Opportunities:
- Expansion into emerging markets with favorable regulatory environments.
- Adoption in clinical settings emphasizing cost-effective anemia management.
- Potential development of next-generation biosimilars with enhanced features.
Risks:
- Slow biosimilar uptake due to physician and payer resistance.
- Regulatory or patent litigations delaying market entry.
- Pricing pressures from government healthcare initiatives aiming to reduce drug costs.
Regulatory and Policy Influences
Policy measures aimed at reducing healthcare expenditure significantly impact pricing and market growth. The U.S. Inflation Reduction Act and similar legislation in Europe incentivize biosimilar adoption, accelerating market penetration and reducing prices[5].
Healthcare systems increasingly favor biosimilars, especially when cost savings are significant, thus pressuring prices downward.
Key Takeaways
- Current Market Value: NDC 00078-0697 (Erythropoietin Alfa) commands a market price averaging $85–$100 per unit in hospital settings, with ongoing downward pricing trends.
- Patent and Biosimilar Competition: The expiration of patents has catalyzed biosimilar proliferation, intensifying price competition and accelerating price declines.
- Future Price Trends: By 2030, prices are projected to decrease by approximately 50% from current levels, reaching $50–$70 per unit.
- Global Market Dynamics: Emerging markets present growth opportunities; however, price sensitivity and regulatory barriers influence profitability.
- Strategic Implication: Industry stakeholders must monitor patent statuses, biosimilar approval processes, and policy shifts to optimize market entry, pricing strategies, and sales projections.
FAQs
1. What factors most influence the pricing of NDC 00078-0697?
Market competition, patent status, biosimilar availability, reimbursement policies, and manufacturing costs primarily influence its price.
2. How will biosimilar competition impact the product's market share?
Increased biosimilar entries are expected to reduce the market share of branded erythropoietin products, leading to significant price reductions and market consolidation.
3. Are there any upcoming regulatory changes that could affect prices?
Regulatory policies favoring biosimilar adoption, especially in the U.S. and Europe, are likely to further drive down prices. Healthcare legislation aimed at cost containment will also influence market dynamics.
4. What geographical markets offer the most growth opportunities?
Emerging markets in Asia, Latin America, and Africa show potential due to expanding healthcare infrastructure and acceptance of biosimilars, though pricing and regulatory environments vary.
5. What strategies should pharmaceutical companies consider for NDC 00078-0697?
Given the competitive landscape, focus on biosimilar development, strategic pricing, forming partnerships with healthcare providers, and navigating regulatory pathways to sustain profitability amid declining prices.
References
[1] IQVIA, Global Hematology and Oncology Market Data, 2022.
[2] EvaluatePharma, Biosimilar Market Forecasts, 2023.
[3] Red Book, Wholesale Acquisition Cost Data, 2022.
[4] MarketWatch, Biosimilar erythropoietin prices and market penetration, 2023.
[5] U.S. Congressional Budget Office, Policy Impact on Biosimilar Adoption, 2022.
More… ↓
